Kornimate/medical-research-clean huggingface dataset:
ai-assisted detection of missed colonic polyps

Conditions: Colon Adenoma; Colonic Polyp; Colon Cancer

Summary: a prospective validation of real time deep learning artificial intelligence model for detection of missed colonic polyps

consecutive adult patients, age 40 or above, who were scheduled to have outpatient colonoscopy in the queen mary hospital were invited to participate. patients were excluded if they were unable to provide informed consent, considered to be unsafe for taking biopsy or polypectomy including patients with bleeding tendency and those with severe comorbid illnesses. also, patients with history of inflammatory bowel disease, familial adenomatous polyposis, peutz-jeghers syndrome or other polyposis syndromes were excluded. the primary endoscopist conducted the colonoscopic examination in the usual manner. all colonoscopy procedures were performed with high-definition colonoscopes (evis-exera 290 video system, olympus optical, tokyo, japan). the colonoscopy was first advanced to the cecum in all patients as confirmed by identification of the appendiceal orifice and ileocecal valve or by intubation of the ileum. after cecal intubation, the colonoscopy was slowly withdrawn to the rectum by the primary endoscopist. the ai real time detection was then activated with the output displayed in a different monitor and was only viewed by an independent investigator, who was an experienced endoscopist. the primary endoscopist was blinded to the ai real time detection result al. the colon was divided into three segments during the examination: right side, transverse and left side colon, using hepatic flexure and splenic flexure as dividing landmark. all polyps were marked for size (measured with biopsy forceps), location and morphology according to the paris classification, and then removed or biopsied for histological examination. after examination of each segment, segmental unblinding of the ai results were provided by the independent viewer. if additional polyps were detected by ai but not by the endoscopist, that segment were reexamined to look for the missed polyp. if no additional polyp was detected by the ai, the next colonic segment was examined. missed lesions were defined as lesions identified by ai and then confirmed on reexamination by the endoscopist. the first withdrawal time (minus the polypectomy site) was measured. the boston bowel preparation scale score (bpps) was used for evaluation of bowel cleanliness.

Eligibility criteria:
inclusion criteria: * consecutive adult patients, age 40 or above, who were scheduled to have outpatient colonoscopy in the queen mary hospital were invited to participate exclusion criteria: * patients were excluded if they were unable to provide informed consent, considered to be unsafe for taking biopsy or polypectomy including patients with bleeding tendency and those with severe comorbid illnesses. * also, patients with history of inflammatory bowel disease, familial adenomatous polyposis, peutz-jeghers syndrome or other polyposis syndromes were excluded.

Keywords: artificial intelligence colonoscopy deep learning detection computer-aided
pharmacokinetics of certoparin in subjects with renal insufficiency and healthy subjects

Conditions: Renal Insufficiency

Summary: this study will assess the pharmacokinetics in subjects with severe renal insufficiency and healthy subjects.


Eligibility criteria:
inclusion criteria: * healthy subjects or * subjects with severe renal insufficiency exclusion criteria: * hypersensitivity to study medication * genetic abnormality or disease of clotting system * prior major surgery or bleeding * other protocol-defined inclusion/exclusion criteria may apply

Keywords: severe renal insufficiency certoparin severe renal insufficiency
uchek pilot study for urinalysis in the antenatal care setting

Conditions: Preeclampsia; Eclampsia; Pregnancy; Proteinuria

Summary: a prospective observational study to test the feasibility of smartphone enabled uchek urinalysis device to detect biomarkers (protein, microalbumin and protein:creatine ratio) in urine, indicative of preeclampsia/eclampsia at over 22 weeks of gestation and assess attitudes of clinicians towards uchek as a new technology for urinalysis.


Eligibility criteria:
inclusion criteria: * pregnant with a gestational age of over 22 weeks and ability to follow pregnancy till delivery. exclusion criteria: * study participant is unwilling to take part in study or participants with pathological conditions that restrict them from providing a urine sample without catheterization.

Keywords: pregnancy preeclampsia eclampsia proteinuria
acute effects of sildenafil on endothelial function in people with diabetes

Conditions: Type 2 Diabetes Mellitus; Endothelial Dysfunction

Summary: this is a double-blind, placebo-controlled, cross-over trial using a single dose of 100 mg sildenafil or placebo in 40 subjects with t2dm without known cardiovascular disease. effects on haemodynamic parameters, flow mediated dilatation (fmd) in brachial artery, cardiovascular autonomic function tests, and spontaneous baroreflex sensitivity (brs) were investigated.


Eligibility criteria:
inclusion criteria: * age 35-70 * type 2 diabetes mellitus * impotence * with and without hypertension, hypercholesteremia exclusion criteria: * patients with history of cardiovascular and malignant disease, * advanced nephropathy (creatinine≥2.2mg/dl) * hepatopathy (liver enzymes higher than the double of normal values) * patients taking nitrates * chf: nyha \> ii * stable angina: ccs \> ii
development of a model to evaluate regenerative endodontic techniques using extract human teeth

Conditions: Dental Pulp Regeneration; Dental Pulp Diseases

Summary: millions of teeth are saved each year by root canal therapy. although current treatment modalities offer high levels of success for many conditions, an ideal form of therapy might consist of regenerative approaches in which diseased or necrotic pulp tissues are removed and replaced with healthy pulp tissue in order to revitalize teeth.

the long term goal of this research project is to develop a method to regenerate dental pulp-like tissue as an alternative method to conventional root canal treatment. the objective of this study is to identify the methods necessary to regenerate dental pulp-like tissue in human teeth. we will collect small (\~4x4mm) pieces of oral mucosa that are normally removed during surgical tooth extractions, isolate human postnatal progenitor/stem cells and, using an in vitro cell culture system, combined isolated cells with various scaffolds and test compounds to determine optimal conditions to differentiate pulp-like tissue (eg, odontoblasts, fibroblasts, endothelium, etc) grown in segments of human roots.

Eligibility criteria:
inclusion criteria: * pre-existing indication for surgical extraction of impacted teeth * age 16-65 exclusion criteria: * ages less than 16 or over 65 * no pre-existing indication for surgical extraction of impacted teeth

Keywords: dental pulp regenerative medicine odontoblasts stem cells growth factor differentiation of stem/progenitor cells odontoblast-specific cell phenotypes
lifestyle intervention in type 2 diabetes

Conditions: Type 2 Diabetes Treated With Insulin

Summary: the purpose of the study is to determine whether a personalized lifestyle intervention focused on diet and physical activity reinforcement is effective in avoiding weight gain in the first months following initiation of subcutaneous insulin pump therapy in type-2 diabetic patients.

patients with type 2 diabetes using insulin pump therapy are gaining weight within the first months of treatment. this weight gain could counterbalance the metabolic benefice of insulin pump treatment in improving glycemic control and could lead to treatment dropout. lifestyle intervention aiming at improving physical activity and diet in type 2 diabetes is known to brought body weight reduction and cardiometabolic improvement. the investigator hypothesized that an intensive, home-based, 6-months diet and physical activity program could prevent the body weight gain associated with insulin pump treatment initiation. the investigator will randomize patients with type 2 diabetes into a "lifestyle intervention" arm or a "usual care" control arm at the time of insulin pump treatment initiation. the primary objective will evaluate body weight change at 6 months after insulin pump treatment initiation. the secondary objectives will evaluate change in glycemic control (hba1c) and body composition at 6 months. in addition, the retention effect will be assessed on body weight change one year after insulin pump treatment initiation, 6 months after the end of the lifestyle intervention.

Eligibility criteria:
inclusion criteria: * adult type 2 diabetic patients with indication of initiation of insulin pump therapy. * patients addressed for the insulin pump follow-up to the home care provider supporting the study. * public health care security affiliation. exclusion criteria: * breastfeeding or pregnant woman. * not willing to participate as assessed by the investigator. * patient engaged in another clinical trial with exclusion criteria for other protocol. * patients unable to ride a training bike. * unavailable in the next 6 months. * patient without a medical certificate done in the last 12 months by a cardiologist attesting the ability to participate in a physical activity reinforcement program.

Keywords: type 2 diabetes lifestyle intervention insulin pump treatment body weight body composition
neoadjuvant paclitaxel poliglumex, cisplatin and radiation for esophageal cancer: a phase ii trial (cti#x64001)

Conditions: Esophageal Cancer

Summary: neoadjuvant paclitaxel poliglumex (ppx; ct-2103), cisplatin and radiation for esophageal cancer: a phase ii trial. (cti#x64001

32 patients with esophageal or gastroesophageal junction cancer will receive radiation:50.4 gy at 180cgy fraction/day for 28 treatments and paclitaxel poliglumex (ppx) and cisplatin weekly times 6 followed by surgery.

Eligibility criteria:
inclusion criteria: * patients are required to have pathologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus or gastroesophageal junction * patients may have celiac adenopathy * there must be no evidence of distant organ metastases * no prior chemotherapy or radiation for esophageal cancer * patients must be \> 18 years of age, and non pregnant * patients must have an anc \> 1,500/ul, platelets \> 100,000/ul, creatinine \< 2.0 and bilirubin \< 1.5 x uln-ecog performance status 0-1. * female patients, must either be not of child bearing potential or have a negative pregnancy test within 14 days of starting study treatment. patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal. pregnant or lactating females are not eligible * no contraindications to esophagectomy * signed informed consent exclusion criteria: * active or uncontrolled infection * patients must not have other coexistent medical condition that would preclude protocol therapy. * any concurrent chemotherapy not indicated in the study protocol or any other investigational agent(s).

Keywords: esophageal cancer
effects of postural and kinesthetic awareness on static standing balance in stroke

Conditions: Chronic Stroke

Summary: the goal of this randomized controlled trial is to check the effects of postural and kinesthetic awareness on static standing balance in chronic stoke patients. participants will be divided into two equal groups. one group will receive routine physical therapy while other group will receive postural and kinesthetic awareness in addition to routine physical therapy.

to determine effects of postural and kinesthetic awareness on plantar pressure and static standing balance in chronic stroke patients. the study was conducted at the university of lahore teaching hospital in the department of pediatric physical therapy \& neuro rehabilitation center. total 62 stroke patients with visual spatial neglect were enrolled in this study, patients were equally assigned into control and experimental group. control group received routine physical therapy while experimental group received routine physical therapy and postural and kinesthetic awareness program. static component of berg balance scale and podata stabiliometeric plate was used for measurement of balance and plantar pressure respectively

Eligibility criteria:
inclusion criteria: * chronic stroke patient * both genders * age: 45-60 years * 9 score or higher on static part of berg balance scale * level 1 and 2 of modified ashworth scale * 24 or more score on mini mental state scale exclusion criteria: * patients with * psychological diseases * dementia * orthopedic disorders * any insufficiency that can influence balance

Keywords: stroke static balance plantar pressure postural and kinestetic awareness podata stabiliometeric plate
deferasirox, cholecalciferol, and azacitidine in the treatment of newly diagnosed aml patients over 65

Conditions: Acute Myeloid Leukemia

Summary: the purpose of this study is to find out if by giving a combination of 3 drugs the leukemia will go into complete remission (meaning the leukemia is completely gone), and to find out how long it stays away. the drugs used in this project are fda approved and commercially available.

the majority of new cases of acute myeloid leukemia (aml) are diagnosed in patients older than 65 years of age. the median age of patients at time of diagnosis is 67 years. standard therapies for aml often have significant toxicity and are poorly tolerated by this patient population. treatment strategies for elderly patients with aml are limited. in those patients who do achieve complete remission, duration of remission tends to be short. treatment at time of relapse is exceedingly difficult and outcomes are dismal. thus, there is need for safer and more effective therapies for elderly patients with aml. this trial is a novel therapeutic combination of deferasirox (exjade), cholecalciferol, and azacitidine in patients 65 years or older with newly diagnosed aml who are not fit for standard induction chemotherapy or hematopoietic stem-cell transplantation.

Eligibility criteria:
inclusion criteria: * 65 or older (must have reached 65th birthday) * morphologically confirmed diagnosis of aml, excluding aml-m3 * must have a zubrod performance status of 0-3 exclusion criteria: * patients with known hiv infection are excluded. if hiv infection is suspected based on clinical condition, testing may be performed at the discretion of treatment team, but is not mandated prior to enrollment. * patients with central nervous system involvement by aml are excluded * patients with history of an active cancer (except basal cell and squamous cell cancers of the skin) within the previous 2 years are excluded

Keywords: azacitidine vidaza deferasirox exjade cholecalciferol vitamin d
perception and equilibrium after cochlear implantation

Conditions: Deafness

Summary: the cochlear implant is an electrical hearing aid that restores the perception of surrounding sounds and speech intelligibility in profoundly deaf patients. during surgery, the labyrinthine break necessary for insertion into the cochlea of the implantable part may cause a malfunction of the vestibular system which can induce dizziness, balance and perception (of the gravitational vertical) disorders. vestibular compensation and new sonic interactions could alter the balance control and the visual and postural spatial orientation perceptions. the usual treatment includes the monitoring of the patient's quality of life, of the vestibular function and of hearing. this study adds an assessment of spatial orientation and of posture.


Eligibility criteria:
inclusion criteria: * profound deaf patients who are scheduled for a cochlear implantation * patients gave their written informed consent * patients are affiliated to the french social welfare exclusion criteria: * disorders from the motor and/or somesthetic systems (especially the lower limbs) * contraindications to the scheduled functional assessments

Keywords: cochlear implant perception posture quality of life
candesartan cilexetil/amlodipine besilate combination tablets ld, hd special drug use surveillance "hypertension: long-term use"

Conditions: Hypertension

Summary: the purpose of this survey is to investigate the safety and efficacy of long-term use of candesartan cilexetil/amlodipine besilate combination tablets (unisia combination tablets) low dose (ld), high dose (hd) in participants with hypertension in the normal clinical setting.

this special drug use surveillance was designed to investigate the safety and efficacy of long-term use of candesartan cilexetil/amlodipine besilate combination tablets (unisia combination tablets) in participants with hypertension in the routine clinical setting. the usual adult dosage is one tablet (8 mg/2.5 mg or 8 mg/5 mg as candesartan cilexetil/amlodipine besilate) administered orally once daily.

Eligibility criteria:
inclusion criteria: 1. participants with hypertension exclusion criteria: 1. participants in whom candesartan cilexetil/amlodipine besilate is contraindicated \[contraindications\] 2. participants with a history of hypersensitivity to the ingredients of candesartan cilexetil/amlodipine besilate or any other dihydropyridine formulations 3. women who are pregnant or of child-bearing potential

Keywords: drug therapy
cumulative irritation test

Conditions: Onychomycosis

Summary: the purpose of this study is to determine the cumulative irritation potential of the products listed by the sponsor.

healthy, adult volunteers of either sex will be patched on his/her back with an2690 solution 2.5%, an2690 solution 5%, an2690 solution 7.5%, an2690 solution vehicle and sodium laurel sulfate 0.5% over the course of 21 consecutive days. after 24 hours, the patches are to be removed and the site evaluated using a five-point scale for irritation.

Eligibility criteria:
inclusion criteria: * healthy, volunteers of either sex, at least 18 years of age or older * females of childbearing potential submitted to a urine pregnancy test and had negative results at day 1 and at the final visit and also was using an effective method of birth control (e.g. abstinence, implants, injectables, oral contraceptives, intrauterine contraceptive devices or double barrier) or agreed to use an effective method of birth control prior to becoming sexual active * subjects were of any skin type or race providing their degree of pigmentation did not interfere with making readings of skin reactions * subjects were willing to follow the study procedures and complete the study * written informed consent was obtained exclusion criteria: * subject with any skin disease that would have in any way confounded interpretation of the study results. atopic dermatitis/eczema, psoriasis or chronic asthma were excluded * subject was pregnant or nursing * subject had a history of sensitivity to any component of any of the formulations * use of chronic medications (such as antihistamines, corticosteroids, analgesics and anti-inflammatories) for one week before and during the study

Keywords: onychomycosis fungal nail
to assess the effects of valsartan on albuminuria/proteinuria in hypertensive patients with type 2 diabetes mellitus

Conditions: Microalbuminuria; Proteinuria

Summary: this study is designed to assess the efficacy of the different dosage forms of valsartan\[80, 160, and 320 mg\] in reducing microalbuminuria/proteinuria in hypertensive patients with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * males or females aged 35 to 75. * type 2 diabetes mellitus (dm) patients coupled with hypertension \[sitting systolic blood pressure (ssbp) 140-179 mm hg and/or sdbp 90-109 mm hg\]. * urinary albumin creatinine ratio (uacr)) indicating microalbuminuria/proteinuria \[30-1000 mg/g or 2.5-25 mg/mmol\] * body mass index (bmi) \<40 kg/m2 * patients who will sign an informed consent. exclusion criteria * type 1 dm * all causes of secondary diabetes mellitus * women of childbearing potential who refuse to use contraception. * pregnant or lactating females. * severe hypertension \[ssbp\> 180 mmhg, sitting diastolic blood pressure (sdbp) \> 110 mmhg \] * patients who are on combo therapy to control bp * patients who are already on valsartan. * hypersensitivity to valsartan. * renal artery stenosis \[ unilateral or bilateral\] * patients taking β blockers, (angiotensin converting enzyme inhibitor (acei) or spironolactone * heart failure * history of myocardial infarction, percutaneous transluminal coronary angioplasty(ptca) or cerebrovascular accident within the preceding 3 months. * creatinine levels \> 1.4 mg/dl \[ 0.07mmol/l\]. liver enzymes \> 2 times upper limit of the normal range(uln). diabetic keto-acidosis (dka) within the last 6 months. presence of diabetic neuropathy or retinopathy. diabetic foot complications. presence of infection at time of screening. hyperkalemia (serum k+ \> 5.5 mmol/l)

Keywords: microalbuminuria/proteinuria hypertensive patients with type 2 diabetes valsartan microalbuminuria/proteinuria in hypertensive patients with type 2 diabetes
effectiveness of a supervised hospital-based physical exercise

Conditions: Stress, Psychological; Anxiety

Summary: to assess if physical activity is effective in reducing stress and anxiety in healthcare professionals.

to assess if physical activity is effective in reducing stress and anxiety in healthcare professionals. to evaluate if physical activity is effective in improving the physical and mental state of health care professionals and improving several blood parameters (lipid profile and blood glucose).

Eligibility criteria:
inclusion criteria * apt for sports practice after review by the corresponding health professional of the occupational health service, * motivation for sports practice (could be self-referred or on an eva scale from a score for example of 6) being 0 not motivated at all and 10 totally motivated. one could extrapolate the score limits of the eva scale pain no motivation=0; mild motivation=1,2; moderate=3-5; high from 6. * professionals whose working day does not coincide with the hours during which the sessions are to be given. * professionals who do not work shifts. exclusion criteria: * any type of contraindication for sports practice (annex i), * staff who, due to their activity, have greater mobility in the hospital (orderlies). * osteoarticular injuries, cervical and lumbalgias. withdrawal criteria -within the intervention group - absence maximum two weeks to the exercises. this will not be taken into account during the summer period.